Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NT-219 by Purple Biotech for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
NT-219 is under clinical development by Purple Biotech and currently in Phase II for Recurrent Head And Neck Squamous Cell...